Timothy Voorhees
YOU?
Author Swipe
View article: Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world? Open
Introduction: Older adults (OAs) with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients (pts). NAVD has been widely adopted in clinical practice for frontline (1L) treatment of OAs with advanced stage cHL…
View article: A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study Open
Introduction: NAVD has become a standard-of-care for frontline (1L) treatment (tx) of advanced stage cHL, based on the results of the S1826 study. S1826 demonstrated a 1-year progression free survival (PFS) of 94% for NAVD compared to 86% …
View article: A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study
A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study Open
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplant. Therapies include reduction of immunosuppression (RIS), CD20 antibodies and chemoimmunotherapy. R-CHOP yields responses in upwards of 60% of…
View article: Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis
Incidence of severe chemotherapy-associated nausea and vomiting with brentuximab vedotin and AVD in comparison with ABVD using standard anti-emetic prophylaxis Open
Introduction: Chemotherapy-induced nausea and vomiting (CINV) remains an important side effect of chemotherapy for patients with classical Hodgkin's Lymphoma (cHL). The BV-AVD (brentuximab vedotin- doxorubicin, vinblastine, dacarbazine) re…
View article: Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease
Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease Open
Introduction: CD19 targeted chimeric antigen receptor T cell therapy (CART) is standard of care (SOC) treatment (tx) for relapsed/refractory (r/r) B-cell non-Hodgkin's Lymphoma (NHL). Patients (pts) with r/r NHL and concurrent autoimmune d…
View article: Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma
Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma Open
Summary Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T‐cell (CAR‐T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CA…
View article: Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma
Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma Open
Marginal zone lymphoma (MZL) is the third most common B-cell non-Hodgkin lymphoma and tends to follow the relapsing course typical of other indolent lymphomas, meaning that many patients receive multiple lines of therapy. Brüton’s tyrosine…
View article: Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study Open
Given the paucity of age‐specific data about biology, presentation, and treatment outcomes in adults with MZL, we sought to evaluate differences between younger (≤ 70 years) and older (> 70 years) patients with MZL in a large retrospective…
View article: Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B‐Cell Lymphomas Treated at an Adult Versus Pediatric Cancer Center
Differences in Observed Outcomes and Toxicities for Adolescent and Young Adult Patients With Aggressive Mature B‐Cell Lymphomas Treated at an Adult Versus Pediatric Cancer Center Open
Background Treatments for adolescent and young adult (AYA) patients with mature B‐cell lymphomas (MBCL) differ between adult versus pediatric centers, and data are scarce regarding comparative toxicities and outcomes. Procedures We identif…
View article: Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies Open
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphomas and multiple myeloma (MM). While data pertaining to the efficac…
View article: Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma Open
Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust analysis. Hence, we …
View article: Outcomes of <scp>CD19 CAR</scp> T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma
Outcomes of <span>CD19 CAR</span> T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma Open
Chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment of aggressive large B‐cell lymphoma (aLBCL). Patients with transformed indolent non‐Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes of CAR f…
View article: A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report
A patient with concurrent EBV-negative diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma: a case report Open
Introduction Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma that accounts for approximately a quarter of all lymphomas in the United States. It is rare to have co-occurring T cell lymphoma with DLBCL as…
View article: Comparison of Treatment Outcomes with V-EPOCH Vs DA-EPOCH for First-Line Plasmablastic Disease
Comparison of Treatment Outcomes with V-EPOCH Vs DA-EPOCH for First-Line Plasmablastic Disease Open
Background: Plasmablastic lymphoma (PBL) is a rare, aggressive B cell non-Hodgkin lymphoma. Plasmablastic myeloma (PBM) is a rare, aggressive form of multiple myeloma (MM), typically defined by presence of ≥2% clonal plasmablasts, and carr…
View article: Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial Open
Background: Improving outcomes with frontline treatment remains a priority for large B-cell lymphoma (LBCL). Dose adjusted (DA) R-EPOCH is commonly used as frontline therapy in specific sub-groups including double hit lymphoma (DHL) and pr…
View article: Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM)
Impact of Baseline Osseous Involvement on Outcomes in Patients with Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom's Macroglobulinemia (WM) Open
Background: Lymphoplasmacytic lymphoma (LPL) is an indolent B-cell non-Hodgkin lymphoma that can involve the bone marrow and cause a monoclonal IgM proteinemia, in which case it is considered Waldenstrom's macroglobulinemia (WM). Involveme…
View article: Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Open
Background: The cornerstone of ICANS pathogenesis is endothelial dysfunction leading to blood-brain barrier disruption driven by inflammatory cytokines. Endothelial dysfunction is often associated with complement activation as in post-tran…
View article: A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study
A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study Open
Background: Follicular lymphoma (FL) is the most common subtype of indolent B-cell non-Hodgkin lymphoma. Six cycles of bendamustine and rituximab (BR) is standard of care for high tumor burden follicular lymphoma (HTBFL). In the BRIGHT tri…
View article: Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis Open
Background: Lymphoplasmacytic lymphoma (LPL) is a rare indolent disease characterized by malignant proliferation of B-lymphocytes with plasmacytic differentiation and typically has MYD88 mutation. An IgM monoclonal gammopathy and bone marr…
View article: Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis Open
Introduction In addition to chimeric antigen receptor T-cell therapy (CAR-T), 6 novel agents are approved in the United States for relapsed/refractory (r/r) large B-cell lymphoma (LBCL): polatuzumab (pola) in combination with bendamustine …
View article: Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis Open
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can aff…
View article: Epigenetic Activation of the EBV Protein Kinase Determines Antiviral Drug Response in Central Nervous System Lymphoma
Epigenetic Activation of the EBV Protein Kinase Determines Antiviral Drug Response in Central Nervous System Lymphoma Open
Epstein-Barr virus (EBV)-associated central nervous system lymphoproliferative diseases (CNSL) are aggressive clinical conditions with poor prognosis. We have reported that durable responses in patients with primary CNS post-transplant lym…
View article: Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma Open
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Robust biomarkers and a complete understanding of CAR T-cell function in the postinfusion phase remain l…
View article: SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program Open
Chimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular immunotherapy is cur…